Prognostic value of pretreatment volume-based quantitative ¹⁸F-FDG PET/CT parameters in patients with malignant pleural mesothelioma

详细信息    查看全文

• 作者：Kazuhiro Kitajima^a ; ¹ ; ^{kitajima@med.kobe-u.ac.jp} ; ^{kazu10041976@yahoo.co.jp} ; Hiroshi Doi^b ; ¹ ; ^{h-doi@hyo-med.ac.jp} ; Kozo Kuribayashi^c ; ^{kuririn@hyo-med.ac.jp} ; Masaki Hashimoto^d ; ^{kogekogemasaki@gmail.com} ; Tatsuya Tsuchitani^e ; ^{tty-823@hyo-med.ac.jp} ; Masao Tanooka^e ; ^{masao1108@gmail.com} ; Kazuhito Fukushima^a ; ^{fukuchan00106@gmail.com} ; Takashi Nakano^c ; ^{t-nakano@hyo-med.ac.jp} ; Seiki Hasegawa^d ; ^{hasegawa@hyo-med.ac.jp} ; Shozo Hirota^b ; ^{hirota-s@hyo-med.ac.jp}
• 关键词：Malignant pleural mesothelioma ; Survival ; Maximum standardized uptake value ; Metabolic tumor volume ; Total lesion glycolysis
• 刊名：European Journal of Radiology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：86
• 期：Complete
• 页码：176-183
• 全文大小：942 K
• 卷排序：86

文摘

To investigate the relationships between pretreatment volume-based quantitative 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters and overall survival (OS) in patients with malignant pleural mesothelioma (MPM).Materials and methodsWe retrospectively reviewed data from 201 MPM patients, of whom 38 underwent surgical resection, and calculated the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), including primary tumors and nodal or distant metastatic lesions, on pretreatment 18F-FDG PET/CT. Relationships between clinicopathological factors (age, sex, performance status, European Organization for Research and Treatment of Cancer [EORTC] score, histological subtype, TNM stage, and treatment strategy), volume-based quantitative PET/CT parameters, and OS were evaluated using a Cox proportional hazards model and log-rank test.ResultsThe median follow-up was 15 months (range, 1–96 months; median, 17 months). In a univariate analysis of all patients, older age (p < 0.05), high EORTC score (p < 0.001), non-epithelioid histological subtype (p < 0.001), high T stage (p < 0.001), positive N/M status (p < 0.05, p < 0.001), advanced TNM stage (p < 0.001), non-surgical treatment (p < 0.001), and high SUVmax (p < 0.001), MTV (p < 0.001), or TLG (p < 0.001) were associated with significantly shorter OS. A multivariate analysis confirmed non-epithelioid subtype (hazard ratio [HR]: 1.69, 95% confidence interval [CI]: 1.14–2.48; p < 0.05), non-surgical treatment (HR: 0.58, 95% CI: 0.34–0.95; p < 0.05), and high TLG (HR: 1.97, 95% CI: 1.14–3.44; p < 0.05) as independent negative predictors.ConclusionsPretreatment volume-based quantitative 18F-FDG PET/CT parameters, especially TLG, could serve as potential surrogate markers for MPM prognosis.